The Immune Change of the Lung and Bowel in an Ulcerative Colitis Rat Model and the Protective Effect of Sodium Houttuyfonate Combined With Matrine.
adaptive immunity
inherent immunity
lung injury
sodium houttuyfonate combined with matrine
ulcerative colitis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
03
2022
accepted:
30
05
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
20
7
2022
Statut:
epublish
Résumé
To explore the immune change of lung injury of Ulcerative colitis (UC) by observing the changes of inherent immunity and adaptive immunity of the lung and bowel in UC rat models after the treatment of Sodium Houttuyfonate combined with Matrine. UC rat models were established with the mucous membrane of colon allergize combined with TNBS-alcohol enteroclysis for 1 week and 5 weeks. 1-week experimental rats were divided into normal group and model group, 5/each group. 5-weeks experimental rats were divided into normal group, model group, Sodium Houttuyfonate (2.9mg/ml) combined with Matrine (1.47mg/ml), and positive control sulfasalazine (10mg/ml), 5/each group. All rats were administered by gavage for 5 weeks. The histopathological and fibrotic changes in the lung and bowel were observed, and the expressions of Tumor Necrosis Factor (TNF)- α, interleukin (IL)-8 in the lung, bowel, and serum were detected by radio-immunity and immunohistochemistry, and the mRNA expressions of Toll-like receptor (TLR)-4, nuclear factor kappa (NF-κB), Macrophage migration inhibitory factor (MIF), Mucosal addressing cell adhesion molecule-1 (MadCAM1) and Pulmonary surfactant protein-A (SP-A) in the lung and bowel were detected by Real time-PCR. Compared with the normal group, the model rats had significant histopathological and fibrotic changes both in the lung and bowel, and all treatment groups were improved. After treatment, TLR4, IL-8, MIF, and TNF-α in the lung decreased (P<0.05); NF-KB, IL-8, and MIF in the bowel increased (P<0.05); MadCAM1 both in lung and bowel decreased (P<0.05); SP-A decreased in bowel and increased in the lung (P<0.05). The cause of lung injury in this model was found to be related to inherent immunity and adaptive immunity, while the cause of bowel injury in this model was found to be mainly related to adaptive immunity. Sodium Houttuyfonate combined with Matrine could improve bowel and lung injury.
Identifiants
pubmed: 35844499
doi: 10.3389/fimmu.2022.888918
pmc: PMC9280623
doi:
Substances chimiques
Alkaloids
0
Alkanes
0
Interleukin-8
0
NF-kappa B
0
Quinolizines
0
Sulfites
0
Tumor Necrosis Factor-alpha
0
sodium houttuyfonate
0
Matrines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
888918Informations de copyright
Copyright © 2022 Ni, Jing, Zhu, Yang, Wang and Tu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2452-7
pubmed: 14983030
Biomed Rep. 2020 Apr;12(4):193-198
pubmed: 32190307
Am J Obstet Gynecol. 2021 Jul;225(1):89.e1-89.e16
pubmed: 33412130
Front Immunol. 2022 Jan 11;12:817583
pubmed: 35087537
Nature. 1995 Sep 7;377(6544):68-71
pubmed: 7659164
Cell Cycle. 2021 Dec;20(23):2547-2564
pubmed: 34747340
Bioorg Med Chem. 2012 Apr 15;20(8):2638-44
pubmed: 22421276
Dev Comp Immunol. 2022 Feb;127:104292
pubmed: 34656643
J Gastroenterol Hepatol. 2003 May;18(5):560-9
pubmed: 12702049
Cureus. 2021 Mar 31;13(3):e14216
pubmed: 33948406
Immunology. 2021 Sep;164(1):173-189
pubmed: 33964011
Autophagy. 2016 Jun 2;12(6):907-16
pubmed: 27163877
J Ethnopharmacol. 2021 Apr 6;269:113735
pubmed: 33359865
Arch Intern Med. 1976 Apr;136(4):454-9
pubmed: 1267553
J Med Case Rep. 2008 Feb 25;2:59
pubmed: 18298838
J Huazhong Univ Sci Technolog Med Sci. 2014 Dec;34(6):815-820
pubmed: 25480575
Am J Transl Res. 2019 Nov 15;11(11):7074-7083
pubmed: 31814910
Oxid Med Cell Longev. 2019 Apr 28;2019:7850324
pubmed: 31182999
Hepatogastroenterology. 2015 Mar-Apr;62(138):309-18
pubmed: 25916055
J Intern Med. 2017 Dec;282(6):522-536
pubmed: 28857295
Mol Med Rep. 2019 Jul;20(1):455-462
pubmed: 31180535
J Periodontol. 2021 Nov;92(11):103-115
pubmed: 33913537
IUBMB Life. 2021 Jul;73(7):900-915
pubmed: 34033211
Inflammopharmacology. 2018 Dec;26(6):1399-1413
pubmed: 30318564
Life Sci. 2019 Sep 15;233:116671
pubmed: 31336122
Br Med J (Clin Res Ed). 1986 Dec 13;293(6561):1537
pubmed: 3099947
Scand J Gastroenterol Suppl. 1996;216:149-59
pubmed: 8726287
HNO. 2016 Sep;64(9):671-5
pubmed: 27421983
Dan Med J. 2015 Jan;62(1):B4973
pubmed: 25557335
Chin J Integr Med. 2016 Dec;22(12):894-901
pubmed: 24938448
Eur J Gastroenterol Hepatol. 2020 Dec;32(12):1527-1532
pubmed: 32976192
Curr Top Med Chem. 2016;16(28):3365-3378
pubmed: 27150374
Mucosal Immunol. 2020 May;13(3):413-422
pubmed: 32112046
Front Pediatr. 2022 Jan 07;9:799693
pubmed: 35071140
South Med J. 1985 May;78(5):624-5
pubmed: 3992313
Biochemistry. 2006 Jul 18;45(28):8657-64
pubmed: 16834340
Sci Transl Med. 2017 Feb 8;9(376):
pubmed: 28179507
J Exp Med. 1994 Jun 1;179(6):1895-902
pubmed: 8195715
World J Gastroenterol. 2010 Oct 21;16(39):4952-7
pubmed: 20954282
Bioorg Med Chem Lett. 2015 Jan 1;25(1):142-7
pubmed: 25467165
Evid Based Complement Alternat Med. 2018 Nov 18;2018:1024634
pubmed: 30581478
J Basic Clin Physiol Pharmacol. 2018 Dec 19;30(1):1-10
pubmed: 30063466
Inflamm Bowel Dis. 2011 Oct;17(10):E137-8
pubmed: 21761513
Front Pharmacol. 2020 Jan 20;10:1552
pubmed: 32038240
Bone Marrow Transplant. 1998 May;21(9):951-4
pubmed: 9613791
Biosci Rep. 2020 Sep 30;40(9):
pubmed: 32915230
World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):560-9
pubmed: 25400999
Gastroenterology. 1979 Nov;77(5):1091-3
pubmed: 582812
FASEB J. 2021 May;35(5):e21418
pubmed: 33774873
N Engl J Med. 1968 Dec 19;279(25):1376-7
pubmed: 5697529
Shock. 2018 Nov;50(5):595-605
pubmed: 29324628
Ger Med Sci. 2015 Mar 30;13:Doc03
pubmed: 25834480
Neurogastroenterol Motil. 2015 Apr;27(4):509-23
pubmed: 25690069
J Ethnopharmacol. 2021 Apr 6;269:113716
pubmed: 33352238
J Intensive Care Med. 2019 Aug;34(8):662-668
pubmed: 28506137
Cell Rep Med. 2021 May 07;2(5):100262
pubmed: 34095875
J Crohns Colitis. 2020 Jan 1;14(1):79-95
pubmed: 31206576